Monitoring the P-ERK status in biopsies of NSCLC patients entering clinical trials of the newly introduced inhibitors of MEK1 will help to assess whether an activated ERK1/2 pathway is necessary for a MEK1 inhibitor to be effective, a question that at present remains unanswered. Here, MAPK1 is linked to non-small cell lung carcinoma.